CVKD insider transaction filings
Cadrenal Therapeutics, Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-01. Screen CVKD transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 3 filings by 1 insider — 30,000 shares, $96,171 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 9,167 shares @ $3.55 ($32,543) by Pham Quang X, filed 2026-06-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Pham Quang X — Chairman and CEO, Director, 10% owner | 3 | — | 5 legs · 30,000 sh · $96,171 | — |
Recent Form 4 filings — Cadrenal Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Pham Quang X — Chairman and CEO, Director, 10% owner | Sale (S): 7,400 @ $3.03 | EDGAR |
| 2026-06-26 | 4 | Pham Quang X — Chairman, CEO and Interim CFO, Director, 10% owner | Sale (S): 2,127 @ $3 · Sale (S): 9,029 @ $3.05 | EDGAR |
| 2026-06-24 | 4 | Pham Quang X — Chairman, CEO and Interim CFO, Director, 10% owner | Sale (S): 9,167 @ $3.55 · Sale (S): 2,277 @ $3.20 | EDGAR |
| 2026-06-18 | 4 | Pham Quang X — Chairman, CEO and Interim CFO, Director, 10% owner | Sale (S): 3,613 @ $3.18 · Sale (S): 513 @ $3.16 | EDGAR |
| 2026-06-15 | 4 | Pham Quang X — Chairman, CEO and Interim CFO, Director, 10% owner | Sale (S): 1,462 @ $4.12 · Sale (S): 12,996 @ $3.94 · Sale (S): 3,666 @ $3.58 | EDGAR |
| 2026-06-10 | 4 | Pham Quang X — Chairman, CEO and Interim CFO, Director, 10% owner | Sale (S): 5,893 @ $4.38 · Sale (S): 12,992 @ $4.06 · Sale (S): 3,500 @ $4.21 | EDGAR |
| 2026-06-05 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 2,323 @ $4.26 · Sale (S): 3,898 @ $4.41 · Sale (S): 2,064 @ $4.42 | EDGAR |
| 2026-06-02 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 303 @ $5.01 · Sale (S): 349 @ $4.46 | EDGAR |
| 2026-05-29 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 6,476 @ $5.76 · Sale (S): 3,298 @ $5.28 · Sale (S): 2,989 @ $4.93 | EDGAR |
| 2026-05-26 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 1,165 @ $5.69 | EDGAR |
| 2025-12-31 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 9,933 @ $6.97 | EDGAR |
| 2025-12-03 | 4 | Golden Lee Scott — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-10-28 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 1,129 @ $14.03 · Sale (S): 1,315 @ $13.99 | EDGAR |
| 2025-10-28 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 1,800 @ $13.99 · Sale (S): 1,800 @ $13.99 | EDGAR |
| 2025-10-14 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 1,800 @ $14.02 · Sale (S): 1,800 @ $14.15 | EDGAR |
| 2025-10-14 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 1,693 @ $13.99 · Sale (S): 1,800 @ $14.07 | EDGAR |
| 2025-10-07 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 107 @ $13.99 | EDGAR |
| 2025-10-03 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 500 @ $14.13 | EDGAR |
| 2025-10-01 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 419 @ $14.01 · Sale (S): 881 @ $14.01 | EDGAR |
| 2025-10-01 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 100 @ $14 · Sale (S): 1,700 @ $13.99 | EDGAR |
| 2025-09-26 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 2,581 @ $13.99 · Sale (S): 6,790 @ $14.09 | EDGAR |
| 2025-09-26 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 1,500 @ $14.00 · Sale (S): 10,900 @ $14.05 | EDGAR |
| 2025-08-29 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Sale (S): 3,836 @ $13.99 · Sale (S): 1,193 @ $13.99 | EDGAR |
| 2025-08-29 | 4 | Szot Matthew K — Chief Financial Officer | Sale (S): 1,600 @ $13.99 · Sale (S): 400 @ $14 | EDGAR |
| 2025-03-24 | 4/A | Pham Quang X — CEO and Chairman, Director, 10% owner | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Ferguson James J. III — Chief Medical Officer | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Lisicki Robert — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Cole Jeffrey Scott — Chief Operating Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Zelenkofske Steven — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | WILSON GLYNN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Szot Matthew K — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | MURPHY JOHN RAYMOND — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-04-10 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Gift (G): 50,000 @ $0 | EDGAR |
| 2024-04-03 | 4 | Cole Jeffrey Scott — Chief Operating Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Pham Quang X — CEO and Chairman, Director, 10% owner | Gift (G): 85,000 @ $0 | EDGAR |
| 2024-01-19 | 4 | Lisicki Robert — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | LOSORDO DOUGLAS W — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Zelenkofske Steven — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | WILSON GLYNN — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Pham Quang X — Chief Executive Officer, Director, 10% owner | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Szot Matthew K — Chief Financial Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | MURPHY JOHN RAYMOND — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cadrenal Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-31 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CVKD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →